共 50 条
- [31] Discovery of novel dihydropteridone derivatives as orally bioavailable PLK1 inhibitors with reduced hERG inhibitory activity for acute myeloid leukemia treatmentEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 289Hou, YunleiLi, ShuangRen, LeZhang, LongZhang, NaMiao, RuifengHuang, QiLi, ZhiweiHu, ChangliangXi, ZhiguoTong, MinghuiGong, PingZhao, YanfangLiu, YajingLiu, Jiuyu
- [32] An orally bioavailable small molecule antagonist of VISTA and VSIG8 signaling pathways shows potent anti-tumor activityJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Sasikumar, PottayilNaremaddepalli, SudarshanRamachandra, RaghuveerGowda, NageshAlluri, GovardhanYerramsetti, ManikyalaraoAdurthi, SreenivasMani, JijuNair, RashmiDhudashiya, AmitDodheri, SamiullaGowda, NagarajRamachandra, Murali
- [33] Discovery of potent and selective inhibitors of USP7 with anti-tumor activity in vitro and in vivoCANCER RESEARCH, 2019, 79 (13)Ohol, Yamini M.Sun, MichaelLeger, PaulHu, DennisBiannic, BerengerRana, PayalCho, CynthiaJacobson, ScottWong, SteveSanchez, JerickHan, XinpingYoung, KyleOkano, AkinoriMaung, JackCutler, GeneShah, NickAdusumilli, LavanyaKaveri, DeepikaTalay, OezcanPookot, DeepaAbraham, BettyBradford, DeliaKozon, NathanColas, ChristopheKim, AndreaSchwarz, JacobWustrow, DavidBrockstedt, DirkKassner, Paul
- [34] CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid LeukemiaJOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (04) : 1835 - 1843Hansen, Joshua D.Correa, MatthewAlexander, MattNagy, MarkHuang, DehuaSapienza, JohnLu, GangLeBrun, Laurie A.Cathers, Brian E.Zhang, WeihongTang, YangAmmirante, MassimoNarla, Rama K.Piccotti, Joseph R.Pourdehnad, MichaelLopez-Girona, Antonia
- [35] Discovery of novel potent and orally bioavailable small-molecule inhibitors of ENPP1 to stabilize cGAMP and ATP in the tumor microenvironment and boost anti-tumor immunity.CANCER RESEARCH, 2021, 81 (13)Versele, MatthiasGarcia, Javier del PinoVandecaetsbeek, IlseCastermans, KarolienKellens, RanieHaeck, WandaKlaassen, HugoBourin, ArnaudDe Clercq, DriesAllasia, SaraBoland, SandroMarchand, ArnaudChaltin, PatrickBollen, Mathieu
- [36] Preclinical assessment of APL-030, a selective and orally bioavailable inhibitor of the integrated stress response regulator GCN2 with activity against acute myeloid leukemiaCANCER RESEARCH, 2024, 84 (06)Roman-Trufero, MonicaWhitlock, GavinFuchter, MatthewJeyakumar, MaxmilaChaida, PanagiotaHerzog, Sereina AnnikZebisch, ArminButt, RichardAuner, Holger W.Clemo, Nadine
- [37] CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML)BLOOD, 2019, 134Lopez-Girona, AntoniaLu, GangRychak, EmilyMendy, DerekLu, Chin-ChunRappley, IritFontanillo, CeliaCathers, Brian E.Daniel, Thomas O.Hansen, Joshua
- [38] Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activitiesBIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 109Zhang, XiaoyuWang, WeiDong, GuoqiangSong, YingqiZhai, XinSheng, Chunquan
- [39] Anti-tumor activity of entrectinib, a highly potent pan-TRK, ROS1 and ALK inhibitor, in molecularly defined acute myeloid leukemiaCANCER RESEARCH, 2017, 77Fagan, PatrickBarrera, MariaWalsh, ColinMurphy, DanielleSilverman, IanShoemaker, RobertWei, GeHornby, ZacharyLi, GarySmith, Kristen M.
- [40] HMPL-500, a potent and selective EZH1/EZH2 dual inhibitor, demonstrates superior anti-tumor activity in preclinical models of hematological malignancies and solid tumorsEUROPEAN JOURNAL OF CANCER, 2024, 211 : S98 - S98Ge, L.Gao, Z.Yu, H.Xue, W.Jiang, A.Chen, S.Zhang, Y.Ding, Q.Li, T.Wang, J.Sai, Y.Yang, N.Qing, W.Ren, Y.Su, W.